Kyverna Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Revenue	0	7.03	5.66
Revenue Growth (YoY)	-	24.20%	-
Gross Profit	0	7.03	5.66
Selling, General & Admin	12.48	8.01	6.15
Research & Development	49.92	28.4	25.85
Operating Expenses	62.41	36.41	32
Operating Income	-62.41	-29.38	-26.35
Interest Expense / Income	0.19	0.07	0
Other Expense / Income	-2.23	-0.56	0
Pretax Income	-60.37	-28.89	-26.35
Net Income	-60.37	-28.89	-26.35
Shares Outstanding (Basic)	1	0	0
Shares Outstanding (Diluted)	1	0	0
Shares Change	47.89%	71.31%	-
EPS (Basic)	-89.61	-63.43	-99.10
EPS (Diluted)	-89.61	-63.43	-99.10
Free Cash Flow	-53.03	-36.88	-23.44
Free Cash Flow Per Share	-78.72	-80.97	-88.17
Gross Margin	-	100.00%	100.00%
Operating Margin	-	-418.28%	-465.81%
Profit Margin	-	-411.29%	-465.88%
Free Cash Flow Margin	-	-525.00%	-414.50%
EBITDA	-56.75	-26.37	-24.93
EBITDA Margin	-	-375.32%	-440.81%
Depreciation & Amortization	3.43	2.46	1.42
EBIT	-60.18	-28.83	-26.35
EBIT Margin	-	-410.36%	-465.82%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).